News

Drug Recall

Drug Recall

April 27, 2015

On April 23, the drug manufacturer Mylan N.V. announced a voluntary nationwide recall of select lots of several drugs used in the treatment of ovarian cancer. The nationwide recall includes several formulations of injectable gemcitabine and cytarabine. While no adverse events have been reported with the use of these drugs, patients who may be experiencing problems related to these drugs should contact their physicians. Expand the post for more information about the recall.

New Ovarian Cancer Dream Team to Research DNA Repair Therapies

New Ovarian Cancer Dream Team to Research DNA Repair Therapies

April 20, 2015

Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition Team-Up to Fund Game-Changing Ovarian Cancer Research Today the members of the new Stand Up To Cancer-Ovarian Cancer Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition Translational Research Dream Team were announced. The Dream Team will focus on “DNA Repair Therapies for … Continued

Announcing the Ovarian Cancer Dream Team!

Announcing the Ovarian Cancer Dream Team!

April 20, 2015

April 20, 2015:   The Ovarian Cancer Dream Team has been chosen! The Dream Team will focus on “DNA Repair Therapies for Ovarian Cancer,” building on recent advances that have identified DNA repair as a common weakness in ovarian cancer. Researchers will also explore the prevention and early detection of ovarian cancer by developing a … Continued

New Recommendations for Ovarian Cancer Prevention

New Recommendations for Ovarian Cancer Prevention

April 16, 2015

(April 16, 2015) The Society of Gynecologic Oncology has published recommendations for prevention of ovarian cancer in Cancer.  Strategies include oral contraceptive use and tubal sterilization, as well as genetic counseling and testing for women from high-risk families. Read the abstract in ACS Journals.

BRCA Cancer Risk Differs With Type and Location of Mutations

BRCA Cancer Risk Differs With Type and Location of Mutations

April 15, 2015

(April 15, 2015) Doctors have long recognized that women with mutations in two particular genes – BRCA1 and BRCA2 – have a higher risk of breast and ovarian cancer. Now they are starting to figure out which mutations are worse than others. They have even discovered that some of these mutations may reduce a woman’s … Continued

Rucaparib Receives Breakthrough Therapy Designation from FDA

Rucaparib Receives Breakthrough Therapy Designation from FDA

April 14, 2015

(April 14, 2015) The FDA granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer. Rucaparib is an oral, small-molecule PARP inhibitor developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough … Continued

OCRF Now Accepting Applications for 2016 Research Grants

OCRF Now Accepting Applications for 2016 Research Grants

April 7, 2015

We are now accepting letters of intent for all research grants. LOIs are due May 8, 2015. Click here for more information.

Microenvironment Regulates Tumor Suppressor miRNA

Microenvironment Regulates Tumor Suppressor miRNA

April 2, 2015

(April 2, 2015) According to a study published in the journal Oncogene, the tumor microenvironment can regulate tumor suppressor miRNA in ovarian cancer cells. The direct interaction of the ovarian cancer cells with mesothelial cells, which cover the surface of the omentum, caused methylation mediated decrease in the expression of miR-193b in the tumor cells. … Continued

Population Distribution of Lifetime Risk of Ovarian Cancer ...

Population Distribution of Lifetime Risk of Ovarian Cancer in the US

April 1, 2015

(April 1, 2015) A study published in Cancer Epidemiology, Biomarkers and Prevention looks at ovarian cancer risk in the general population.  In U.S. women, lifetime risk of ovarian cancer is 1.37%, but some women are at a substantially lower or higher ovarian cancer risk due to both genetic and lifestyle factors. Leigh Pierce, PhD and … Continued

Intraperitoneal Chemo Associated with Long-Term Survival Ad...

Intraperitoneal Chemo Associated with Long-Term Survival Advantage

March 27, 2015

(March 27, 2015) According to research published this week in the Journal of Clinical Oncology, intraperitoneal (IP) chemotherapy is associated with a long-term survival advantage in ovarian cancer.  The advantage of IP over intravenous chemotherapy extends beyond 10 years, and IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number … Continued

Decisions on a Knife-Edge: Risks and Benefits of Fallopian ...

Decisions on a Knife-Edge: Risks and Benefits of Fallopian Tube Removal

March 20, 2015

(March 20, 2015) This excellent, accessible piece in Mosaic Magazine, “Decisions on a Knife-Edge,” explores the difficult choices high-risk women face when considering how to decrease their chances of developing ovarian cancer.  Removing only the fallopian tubes will avoid forcing a woman into early menopause, which is an appealing option for many women.  Yet it’s not … Continued

Tailored Surgical Approach Leads to Better Outcomes in Ovar...

Tailored Surgical Approach Leads to Better Outcomes in Ovarian Cancer

March 10, 2015

(March 10, 2015) An algorithm developed at MD Anderson Cancer Center in Houston has dramatically increased complete resection rates in advanced ovarian cancer, giving patients the best possible chance of survival. The work was funded in part by an OCRF research grant to Anil Sood, MD. The results are summarized in an article in Nature … Continued